← Leaderboards
Terence Marques Williams
Beckman Research Institute/City Of Hope
$5,994,391
Attributed
$8,596,705
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,596,705 · 4
By mechanism
R01$8,596,705 · 4
Top collaborators
- Nicholas C Denko7 shared
- Zihai Li7 shared
- Manisha Shah2 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorStandard Of CareMalignant NeoplasmsNeoplastic CellResponsePathway InteractionsChemotherapyRadiationMutationCellsOncogenicBloodPharmaceutical PreparationsClinical TrialsNormal Tissue MorphologyCell LineGeneticIn Vitro TestingMigrationTumor MicroenvironmentMaximum Tolerated DoseRadiation ResistanceResistanceFda Approved
Grant awards (23)
Tumor-Selective Radiosensitization by Targeting Hypoxia in Rectal Cancer$662,096
R01 · FY2025 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$640,703
R01 · FY2025 · CA
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer$462,998
R01 · FY2025 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$608,669
R01 · FY2024 · CA
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer$194,528
R01 · FY2024 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$627,890
R01 · FY2023 · CA
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer$458,906
R01 · FY2023 · CA · contact PI
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$212,016
R01 · FY2023 · CA
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$632,109
R01 · FY2022 · CA
Diversity Supplement R01CA262388: Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$216,344
R01 · FY2022 · CA
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism$650,406
R01 · FY2021 · CA
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer$445,665
R01 · FY2021 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer$77,289
R01 · FY2021 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer$338,263
R01 · FY2020 · CA · contact PI
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer$226,665
R01 · FY2020 · CA · contact PI
Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer$193,780
R01 · FY2020 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer$124,162
R01 · FY2020 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer$378,304
R01 · FY2019 · CA · contact PI
Exploiting caveolae-dependent albumin endocytosis to optimize therapy in pancreatic cancer$57,182
R01 · FY2019 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer$390,636
R01 · FY2018 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer$397,192
R01 · FY2017 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer$400,902
R01 · FY2016 · CA · contact PI
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer$200,000
R01 · FY2016 · CA · contact PI